ABSTRACT
This study investigated the effects of homocysteine (Hcy) on angiogenesis in cultured human umbilical vein endothelial cells (HUVEC) and zebrafish embryos. We found that Hcy (50 micro mol/L) significantly decreased cell numbers, viability, and induced a G1/S arrest in HUVEC in the presence of adenosine (Ade, 50 micro mol/L). Hcy, in combination with Ade, reduced migration and suppressed tube-like formation on Matrigel in HUVEC. Further, Hcy reduced subintestinal vessel formation in zebrafish embryos. Interestingly, Hcyinduced inhibitory effects on cell growth, migration, tubelike formation, and vessel formation in HUVEC and zebra fish embryos were abolished by the supplement of recombinant VEGF (10ng/ml). Finally, Hcy in combination with Ade reduced the mRNA levels of VEGF, VEGFR-1, VEGFR-2, and attenuated protein levels of VEGF, ERK1/2 and Akt. The present study suggests that Hcy inhibits angiogenesis, and that the mechanism anti-angiogenic effects of Hcy may be through VEGF/VEGFR, Akt, and ERK1/2 inhibition. .
INTRODUCTION
Hyperhomocysteinemia (HHcy) is an established independent and significant risk factor for cardiovascular disease (CVD) and can be classified as moderate (15 to 30µmol/L), intermediate (30 to 100µmol/L), and severe (>100µmol/L) (1, 2) . Several mechanisms including endothelial cell (EC) damage and dysfunction (3) (4) (5) , dyslipidemia (6) , alterations in vessel structure (7, 8) , and stimulation of vascular smooth muscle cell proliferation (9) have been proposed to explain the cardiovascular changes associated with HHcy.
The integrity of vascular endothelium is crucial for physiologic function. In response to injury, ECs undergo an active compensatory process involving proliferation, migration, and angiogenesis to reestablish homeostasis.
Homocysteine (Hcy) has been reported to inhibit angiogenesis in vitro and in vivo (10) (11) (12) . The antiangiogenic effect of Hcy occurs at very high concentrations of Hcy (1-200 mmol/L), which is higher than the concentration of Hcy related CVD. The molecular and biochemical basis by which HHcy inhibits angiogenesis is not clear. Our previous study has shown that HHcy-induced endothelial dysfunction was associated with increased Thr-495 phosphorylation of endothelial nitric oxide synthase(eNOS) through protein kinase C (PKC) activation and decreased Ser-1177 phosphorylation of eNOS through compromised vascular endothelial growth factor(VEGF)/Akt signaling (3, 5) . It is reasonable to ascertain that the VEGF/Akt/eNOS pathway plays a crucial role in angiogenesis (13) .
Recently, it was reported that the specific conversion of Hcy to S-adenosyl Hcy (SAH) represents another mechanism capable of perturbing ECs phenotype (14) . SAH is a potent inhibitor of cellular methylation. Elevated levels of Hcy, in combination with adenosine (Ade), leads to increased levels of SAH and acts to inhibit cellular methylation. Hypomethylation may be a specific biochemical mechanism by which HHcy induces vascular injury (14) (15) (16) .
In the present study, , we studied whether clinically relevant concentrations of Hcy would inhibit angiogenesis through hypomethylation. To test our hypothesis, we measured the effect of Hcy on angiogenesis by examining endothelial cell proliferation, migration, and vessel formation in the zebra fish model and cultured HUVEC at an intermediate concentration of Hcy (50µmol/L) with and without Ade (50µmol/L).
MATERIALS AND METHODS

Cell culture
Primary human umbilical vein endothelial cells (HUVEC) were cultured as previously described (5) . Briefly, HUVEC were isolated from human umbilical veins after 0.25% trypsin (TBD, China) digestion and maintained on gelatin (Acumedia, Lansing, MI, USA) coated T25 flasks in M199 (Hyclone, USA) supplemented with 20% fetal bovine serum (FBS; Hyclone, USA), 50 ug⁄mL endothelial cell growth supplement (ECGS; BD, Bedford, MA, USA), and 50ug⁄mL heparin (DINGGUO, Beijing, China). Cultures were maintained at 37°C in a humidified 5% CO 2 incubator. HUVEC were identified by their typical cobblestone appearance and the presence of von Willebrand Factor (factor VIII). HUVEC from 2-4 passages were used for the experiment.
Cell proliferation assay
HUVEC proliferation was assessed by direct cell counting. Briefly, HUVEC were seeded in 24-well plates at 3×10 4 cells/well. Cells were incubated with PBS, 50µmol/L adenosine (Ade) (Sigma, St Louis, MO), or 50µmol/L DLHcy in the presence or absence of 50µmol/L Ade for 48h. 10µmol/L erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) (Sigma, RBI), an Ade deaminase inhibitor that stabilizes Ade, were added in all the experiments. The addition of Ade served to enhance the conversion of Hcy to SAH. HUVEC were also incubated with PBS, 50µmol/L Ade, or 50µmol/L DL-Hcy in the presence or absence of 50µmol/L Ade in the presence of 10 ng/mL recombinant human VEGF165 (R&D, USA) to examine whether VEGF could counteract the effects of Hcy on HUVEC proliferation. The cells were then trypsinized and cell number was determined by counting with a hemocytometer.
Cell viability assay
Cell viability was assessed using the MTT assay according to manufacture recommendation (Sigma, St Louis, MO, USA). Briefly, HUVEC (1×104 cells/well) were plated onto 96-well plates and routinely incubated for 24h. Cells were then treated with assay media for 48h. MTT reagent was added for the last 4h of incubation. The supernatant was removed and dimethyl sulfoxide (DMSO) (Sigma, St Louis, MO, USA) was added to solubilize the formazan crystals. Absorbance was measured at 492 nm with an enzyme-linked-immunosorbent assay plate reader (Thermo, Boston, Massachusetts, USA)
Cell cycle analysis
To analyze the cell cycle, DNA content was measured by flow cytometry. HUVEC were seeded in 60 mm dishes at the density of 1.25×10 5 cells/dish. After treatment with the assay media for 24h, HUVEC were harvested, adjusted to a concentration of 1×10 6 cells/ml, and fixed in 70% ethanol at 4°C overnight. The fixed cells were washed twice with cold PBS, and then incubated for 30 min with RNase (8 mg/ml) and propidium iodide (10 mg/ml). The cell cycle was then assayed by flow cytometry (EPICS XL-MCL, Beckman Coulter, Florida, USA).
Cell migration assay
Cell migration was measured using a scratch injury assay. After 24 hours of assay media treatment, 90% confluent monolayer of HUVEC were wounded using a micropipette tip (100 µl yellow tip), gently rinsed with PBS, and then incubated in the same assay media. HUVEC migration was photographed using a live cells imaging system(Zeiss Axio Observer Z1,Genmany) in 37 °C and 5% CO 2 humidified atmosphere. Live cells can be photographed every 5 minutes and the results can be exported in way of movies which provided intuitive cell motion images. Individual cell migration was quantified from 3 separate experiments measuring 10 cells per treatment using AxioVision microscope software (Zeiss, Germany) with an automatic and interactive tracking module as described in Starke et al (17) . Parameters including total distance, straight distance, mean velocity, and tortuosity were analyzed.
Matrigel assay
To determine whether Hcy inhibited angiogenesis, we used the experimental in vitro Matrigel system (18) . Matrigel Basement Membrane Matrix (BD, Bedford, USA) was thawed on ice at 4°C overnight and all pipettes and 96-well flat bottom plate were precooled before use. Ninety-six-well plates were coated with 50 µl Matrigel per well. HUVEC were seeded at 4×10 4 cells per well in 100µl assay media. Each group was in triplicate. After 16h of incubation, tube-like structures were photographed using inverted microscope (IX71). The total tube length was quantified using Image J software (NIH, Bethesda, MD, USA). 
Zebrafish embryos angiogenesis assay
Transgenic (flk1:GFP) zebrafish embryos were generated by natural pair-wise mating, collected and maintained in 28.5°C incubator as described before (19) . Healthy, limpid, and fluorescent embryos were picked out at 24 hours post-fertilization (hpf) and distributed into a 96-well microplate (3 embryos/well) containing Holt Buffer. Meanwhile, 50µmol/L Ade, 50µmol/L DL-Hcy, or 50µmol/L DL-Hcy in the presence of 10ng/mL VEGF165 were added to the culture media. PBS served as the control. Embryos were maintained in a 28.5°C incubator for an additional 48h, placed onto a glass slide, and photographed using fluorescence stereomicroscope. The overall length and branch points of the subintestinal vessels (SIVs) were quantified using Image J software. Anti-angiogenic effects were defined as the decrease of SIVs length and branch points (20) .
Quantitative real time PCR for mRNA expression analyses
Total RNA was extracted from the HUVEC cells treated with the assay media for 24h. 500 ng of total RNA from each sample were used for cDNA synthesis using Prime Script RT reagent Kit (TaKaRa). cDNA was subsequently amplified with the SYBR Premix Ex TaqTM Kit (TaKaRa) in 8 Strip PCR tubes using the iQ5 instrument (Roche) as follows: 10 minutes at 95°C for enzyme activation followed by 40 cycles of 15 seconds at 95°C, 20 seconds at 55°C, one second at 72°C for the amplification step, and 30 seconds at 40°C for the cooling step. Changes in the expression of target genes (VEGF, VEGFR1, and VEGFR2) were measured relative to the mean critical threshold (CT) values of β-actin gene. The primers used in the qRT-PCR evaluation were specific for every gene as previously reported (Table 1) (21, 22) . 1µM of both primers were used for all genes.
Western blot analysis
HUVEC were treated with assay media for 48 h. Western blot procedures were carried out as described previously (5) . Briefly, whole cell lysates from each sample were taken after normalizing for equal protein concentration, and were analyzed with specific antibodies against VEGF (1:1000; Abcam, Cambridge, UK), Akt (1:1000; CST, USA), and ERK1/2 (1:1000; CST, USA). Incubation with monoclonal GAPDH antibody (1:10000; Sigma, USA) was carried out as the loading control. The blots were detected on Kodak X-Omat film by enhanced chemiluminescence (Applygen Technologies, Beijing, China). Quantification of band intensity was carried out using Image J software (NIH, Bethesda, MD, USA).
Statistical methods
All data were from at least three independent experiments. Results were expressed as the mean ± SD. Statistical comparison among multiple groups was performed by one-way ANOVA followed by LSD test using the SPSS 17.0 software. A p<0.05 was considered to be statistically significant.
RESULTS
Hcy inhibited HUVEC proliferation and viability
The effect of Hcy on HUVEC proliferation was evaluated by both direct cell counting and the MTT assay. In the presence of Ade, treatment with Hcy significantly decreased cell number and viability of HUVEC, whereas exposure of HUVEC to Hcy alone did not significantly affect cell number and viability when compared to PBS control ( Figure 1A, B) . Thus, Hcy in combination with Ade may inhibit HUVEC proliferation. In addition, we observed that the supplement of recombinant VEGF165 significantly improved Hcy-inhibited HUVEC proliferation and cell viability ( Figure 1A , B).
Hcy induced HUVEC cell cycle G1/S arrest
The DNA content of HUVEC was measured to determine the cell cycle distribution after treatment with the assay medium. The exposure of HUVEC to Hcy in combination with Ade significantly increased the percentage of cells retained in the G1 phase of the cell cycle when compared to PBS control (from 59.9% to 73.1%; P<0.05). In addition, there was a concomitant decrease in cells entering the S phase(Table 2 & Figure  1C ), which represents a G1/S arrest that is induced by Hcy in combination with Ade. No significant change was observed in HUVEC treated with Hcy alone. The supplement of recombinant VEGF165 significantly improved Hcy-inhibited HUVEC cell cycle transition (Table 2 & Figure 1C ).
Hcy inhibited HUVEC migration
We investigated the role of Hcy in HUVEC migration using a scratch wound assay and a live cells imaging system. As shown in Figure 2 , Hcy in combination with Ade significantly decreased HUVEC migratory straight distance, but not total distance when compared to PBS control. This decrease was associated with a loss of directionality. Hcy in combination with Ade also significantly increased the tortuosity of cells movement paths. However, Hcy alone did not impact the migration of HUVEC. The supplement of exogenous VEGF165 significantly improved migratory straight distance and decreased the tortuosity of HUVEC (Figure 2 ).
Hcy suppressed tube formation
We investigated the anti-angiogenesis ability of Hcy using the Matrigel tube formation assay. HUVEC were cultured on Matrigel, a solid gel of mouse basement membrane proteins, which easily align and form hollow tube-like structures. Figure 3A shows the representative micrographs. In HUVEC treated with Hcy and Ade, there are less tube-like structures in comparison to PBS control. Quantitative measurements confirmed that Hcy in combination with Ade triggered a significant decrease in total tube length ( Figure 3B ). As anticipated, the simultaneous treatment of VEGF165 with Hcy significantly restored angiogenesis in vitro.
Hcy inhibited the vessel formation in zebrafish embryo
To study the effect of Hcy on angiogenesis in vivo, transgenic (flk1:GFP) zebrafish embryos, which express GFP in all vascular endothelial cells, were used. The development of zebrafish SIVs was visualized using fluorescence stereomicroscope. SIVs length and branch points number of SIVs were measured with Image J. The representative photos and quantitative analysis of zebrafish SIVs were showed in Figure 4 . As expected, both the length and branch points number of SIVs were significantly decreased in zebrafish embryos treated with Hcy in combination with Ade when compared to PBS control, which indicates an inhibitory effect of Hcy plus Ade on angiogenesis of zebrafish embryo. However, Hcy alone 
Hcy inhibited expression of VEGF, VEGFR1 and VEGFR2
In order to identify the molecular targets of the anti-angiogenic effect of Hcy on HUVEC, we measured mRNA expression of VEGF, VEGFR1 and VEGFR2 by real-time PCR and protein expression of VEGF by Western blot analysis. Treatment of HUVEC with Hcy plus Ade significantly down regulated mRNA expression of VEGF, VEGFR1, and VEGFR2 when compared to PBS control ( Figure 5A ). In contrast, treatment of HUVEC with Hcy alone did not result in significant change of VEGF, VEGFR1, and VEGFR2 mRNA expression. (??)Protein levels of VEGF were also significantly decreased by Hcy plus Ade ( Figure 5B ).
Hcy decreased ERK1/2 and Akt expression in HUVEC
To explore signaling pathways mediating the anti-angiogenic effect of Hcy, we also examined the expression of ERK1/2 and Akt. Figure 6 shows that in comparison to PBS control, protein levels of ERK and Akt were attenuated in the presence of Hcy and Ade.
DISCUSSION
In the present study, we demonstrated that Hcy (50µmol/L) in combination with Ade (50µmol/L) significantly inhibited HUVEC proliferation, migration, tube formation, and angiogenesis in the embryos of zebrafish. Moreover, we observed that the anti-angiogenic effects of Hcy in combination with Ade was associated with VEGF/VEGFR inhibition and a decrease of Akt and ERK1/2.
HHcy is a well established risk factor of CVD (1, 23) . Endothelial dysfunction and damage is an initiated and determined event in the development of CVD. It has been reported that Hcy suppresses nitric oxide (NO) production and impairs endothelium-dependent vasodilatation (24) (25) (26) . Oxidation has been recognized as the primary biochemical mechanism responsible for Hcy pathogenesis(27). Nagai et al observed that Hcy inhibited angiogenesis by preventing EC proliferation and migration (12) . However, very high concentrations of Hcy (1 to 10 mmol/L) was used in their experiments. Our study uses HUVEC and zebrafish embryos model to delineate the mechanisms of how physiological relevant concentration of Hcy (50µmol/L) combined with Ade inhibit angiogenesis. Hcy may interact with Ade, a normal constituent of all body fluids, to become SAH, a potent inhibitor of cellular methylation. Wang et al demonstrated that Hcy increased cellular SAH concentration and exerted highly selective inhibitory effects on cyclin A transcription and EC growth through a hypomethylation related mechanism, which blocked cell cycle progression and endothelium regeneration(28, 29).
As the process of angiogenesis involves coordinated ECs proliferation, we investigated the effect of Hcy on HUVEC proliferation and cell cycle transition. Previous studies have reported that Hcy disrupted the growth of ECs and exhibited delayed progression through the cell cycle at the G1/S transition (21, 29) . Similarly, we found that Hcy combined with Ade induced an obvious G1/S cell cycle arrest and significantly inhibited cell proliferation in HUVEC, whereas Hcy alone did not. In addition, the supplement of recombinant VEGF165 significantly improved Hcy-inhibited HUVEC proliferation and cell cycle transition.
Angiogenesis encompasses many of the steps including cell proliferation and migration(30). We therefore examined the effect of Hcy on HUVEC migration using a scratch wound assay. Using the live cells imaging system and software, the results can be exported in way of movies which provided intuitive cell motion images and thus cell movement paths can be tracked over time. By using this method of tracking, we are able to witness the most visible and direct evidence of migration. We found that Hcy plus Ade significantly decreased migratory straight distance, but not total distance, and that this decrease was associated with a loss of directionality. The movement paths of HUVEC treated with Hcy plus Ade exhibited a significantly higher degree of tortuosity. ECs migration is a prerequisite for angiogenesis. Thus, the inhibition of HUVEC migration indicates impaired angiogenesis ability. We also found that HUVEC migration rescue was achieved with exogenous VEGF165 supplementation.
Organization of ECs into a network of tubes is a late event during angiogenesis. We found that Hcy used in combination with Ade inhibited the formation of tube-like structures on Matrigel, which is an indicator of angiogenesis in vitro (18) . Moreover, we observed the inhibitory effect of Hcy on angiogenesis in vivo in transgenic (flk1:GFP) zebrafish embryos where VEGFR is expressed in all ECs(31). Blood vessel patterning is highly characteristic in the developing zebrafish embryo, and the SIVs can be visualized microscopically as a primary screen for compounds that affect angiogenesis(32). Our results showed that Hcy in combination with Ade inhibited the growth of SIVs in zebrafish embryos. Treatment of embryos with exogenous VEGF165, in addition to Hcy plus Ade, significantly improved angiogenesis in zebrafish embryos. Taken together, our present study and previous data predict that Hcy in combination with Ade might primarily exert its anti-angiogenic effect via a hypomethylation mechanism; the impacts of Hcy alone might be injurious through oxidative mechanism at high concentrations. Future research is needed to explore the direct relationship between Hcy-induced hypomethylation and angiogenesis. Several growth factors have been shown to be crucial for angiogenesis. The well-known angiogenic factor VEGF promotes EC proliferation, migration, and tube formation (33, 34) . Both VEGF, which is expressed in the vicinity of sprouting vessels, and its receptor, VEGF-R2/Flk-1/KDR,, are required for angiogenesis (35, 36) . The subsequent stimulation of VEGFR results in a molecular cascade leading to EC mitosis and migration into the perivascular space (37) . We examined the effect of Hcy on the expression of VEGF and VEGFR. Proteomic analysis indicated that Hcy inhibited microvascular ECs angiogenesis partly by decreasing VEGF (38) . Chang (21) reported that, in combination with Ade, Hcy reduced VEGF expression in a dose and time-dependent manner and reached a significantly reduction when Hcy was raised to 500 µmol/L in bovine aortic ECs and human coronary arterial ECs. Results from our experiments showed that Hcy in combination with Ade significantly decreased VEGF mRNA and protein expression in HUVEC. We speculate that this difference may be due to 1) VEGF protein levels were examined after Hcy treatment for 24h and 48h in Chang's study and the present experiments respectively; 2) different methods were used in these experiments. Intracellular VEGF levels were assayed by ELISA in Chang's study, and by real-time PCR and Western blot in the present study; and 3) different kinds of ECs were used in Chang's study compared to the present (42, 43) . VEGF is an important regulator in ECs function and exerts this effect through ERK and Akt signaling pathway. Angiogenic inducers have been shown to increase the angiogenic process by activating angiogenic signal mediators such as ERK and Akt, as well as by upregulating pro-angiogenic gene expression including VEGF (43) (44) (45) . We observed that Hcy in combination with Ade significantly decreased the protein levels of ERK1/2 and Akt as determined by Western blot analysis. Thus, the suppression of ERK1/2 and Akt might be responsible for the anti-angiogenic effect of Hcy in vitro and in vivo.
In summary, the present study revealed that clinically relevant concentrations of Hcy in combination with Ade inhibited angiogenesis both in vitro and in vivo. We proposed the hypothesis that elevated Hcy in combination with Ade may lead to decreased angiogenesis by hypomethylation, given the propensity for Hcy to convert to SAH. The anti-angiogenic effect of Hcy may be associated with inappropriate gene expression of VEGF/VEGFR, ERK1/2, and Akt by shifting the cellular methylation potential. The characteristics and key links involved in the proposed pathogenic mechanisms still need to be investigated. Our findings pose challenges for future studies as angiogenesis plays a crucial role in different physiological and pathological processes, such as embryonic development, wound repair, tumor growth, and atherosclerosis. Understanding further the mechanism by which the anti-angiogenic effect of Hcy occurs will lead to the development of novel therapies. 
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